ReviewSeminars in perinatology2010
Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.
Review in Seminars in perinatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions.The Cochrane database of systematic reviews · 2018Pooled it
- Chorioamnionitis appears not to be a Risk Factor for Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Caffeine-associated reduction in patent ductus arteriosus is mediated in part by adenosine receptor antagonism.American journal of physiology. Heart and circulatory physiology · 2025Article
- Article
- Patent Ductus Arteriosus in Extremely Preterm Infants: Update on Current Diagnostic and Treatment Options.Current treatment options in cardiovascular medicine · 2025Review
- Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.Developmental dynamics : an official publication of the American Association of Anatomists · 2022Review
- Use of Prostaglandin E1 in the Management of Congenital Diaphragmatic Hernia-A Review.Frontiers in pediatrics · 2022Review
- Association of chorioamnionitis and patent ductus arteriosus in a national U.S. cohort.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Early Urinary Metabolomics in Patent Ductus Arteriosus Anticipates the Fate: Preliminary Data.Frontiers in pediatrics · 2020Article
- Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.Seminars in fetal & neonatal medicine · 2018Review
- Diagnosis and Management of Patent Ductus Arteriosus.NeoReviews · 2018Article
- Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.Journal of perinatology : official journal of the California Perinatal Association · 2017Observational
- Congenital Heart Disease Requiring Maintenance of Ductus Arteriosus in Critically Ill Newborns Admitted at a Tertiary Neonatal Intensive Care Unit.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2016Article
- Aminoglycoside-mediated relaxation of the ductus arteriosus in sepsis-associated PDA.American journal of physiology. Heart and circulatory physiology · 2014Article
- Pharmacogenetics in clinical pediatrics: challenges and strategies.Personalized medicine · 2013Article
- Results of a two-center, before and after study of piperacillin-tazobactam versus ampicillin and gentamicin as empiric therapy for suspected sepsis at birth in neonates ≤ 1500 g.Journal of perinatology : official journal of the California Perinatal Association · 2013Observational
- Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.Journal of molecular and cellular cardiology · 2013Article
- Antenatal calcium channel blocker exposure and subsequent patent ductus arteriosus in extremely low-birth-weight infants.Pediatric cardiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Premature birth and disruption of the normal maturation process leave the immature ductus arteriosus unable to respond to postnatal cues for closure. Strategies that advocate conservative management of the patent ductus arteriosus (PDA) in premature infants are dependent on identification of the symptomatic PDA and understanding the risk factors that predispose to PDA. Exposure of premature infants to unintended vasodilatory stimuli may be one of the risk factors for PDA that is under recognized. In this article, we summarize the clinical factors that are associated with PDA and review commonly used neonatal drugs for their vasodilatory properties. Data demonstrating relaxation of the ductus arteriosus by gentamicin and other aminoglycoside antibiotics, by cimetidine and other H2 receptor antagonists, and by heparin are provided as examples of neonatal therapies that have unanticipated effects that may promote PDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.